The company incurred a loss in its most recent quarterly results.

Pfizer is ramping up plans for tilrekimig after a phase 2 win raised hopes that the once-monthly trispecific antibody could hold its own against approved eczema drugs. | Pfizer is ramping up plans for ...

By Padmanabhan Ananthan March 9 (Reuters) - U.S. drugmaker Pfizer said on Monday its experimental drug for a chronic skin ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) ...

Pfizer ( PFE) said its Phase 2 study of tilrekimig (PF-07275315), a trispecific antibody for atopic dermatitis, showed ...

By Andrew Silver SHANGHAI, March 6 (Reuters) - China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight ...

One of the most powerful voices in the biopharma industry, Pfizer CEO Albert Bourla, Ph.D., has weighed in with sharp ...

Pfizer received its first obesity drug approval in China for Severwin, opening a new market for the company. The company also ...

Explore Pfizer’s evolving pipeline strategy, expanding into oncology and obesity to drive growth beyond its COVID-19 success.

Those were in great demand at the beginning of the pandemic, and generated gobs of money for Pfizer. Demand has waned, though ...

Less than two weeks after Pfizer struck a deal with a Chinese drugmaker to gain commercial rights to a GLP-1 drug, the country’s National Medical Products Administration (NMPA) has ...

Agreement worth up to $495 million is part of a growing number of Chinese deals with global pharma giants as the country ...